SCHEMBL1180248

SCHEMBL1180248

CC(C)Cc1cc(C(=O)O)nc(N(C)C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
ALOX15 P16050 2/20 0.35
TSHR P16473 1/20 0.35
HIF1A Q16665 1/20 0.35
ALDH1A1 P00352 5/20 0.35
CTSA P10619 3/20 0.35
KDM4E B2RXH2 3/20 0.35
HSD17B10 Q99714 1/20 0.35
HPGD P15428 1/20 0.34
IKBKB O14920 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ESR1 P03372 1/20 0.33
HCAR3 P49019 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
ALPL P05186 1/20 0.32
GAA P10253 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179269 0.82 HCAR2 (0.39) ALOX15TSHRHIF1AALDH1A1CTSA
SCHEMBL24754504 0.82 HCAR2 (0.39) NOS3NOS1NOS2ALOX15TSHR
SCHEMBL1178845 0.79 KDM4E (0.43) NOS3NOS1NOS2ALOX15TSHR
SCHEMBL27828594 0.76 CTSA (0.37) NOS3NOS1NOS2ALOX15TSHR
SCHEMBL1178906 0.76 NOS2 (0.54) NOS3NOS1NOS2ALOX15TSHR
SCHEMBL1179525 0.75 LMNA (0.57) NOS3NOS1NOS2ALOX15TSHR
SCHEMBL1178563 0.75 ESR1 (0.42) NOS3NOS1NOS2ALOX15TSHR
Hydrochloric Acid SCHEMBL1424993 0.74 NOS2 (0.53) NOS3NOS1NOS2ALOX15TSHR
SCHEMBL12120830 0.74 FABP3 (0.41) NOS3NOS1NOS2ALOX15TSHR
SCHEMBL1179003 0.74 ESR1 (0.41) NOS3NOS1NOS2ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
CN-101965346-A Novel pyrimidine-pyridine derivatives ACTELION PHARMACEUTICALS LTD 2011-02-02 CN disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD NOS3 3058/4885NOS1 3131/4885NOS2 2520/4885
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 NOS3 2507/4885NOS1 2770/4885NOS2 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.